Table of Contents: CATIE TreatmentUpdate

Table of Contents: CATIE TreatmentUpdate - 2001

Canadian AIDS Treatment Information Exchange
Edited by: Sean Hosein

Jump to Table of Contents

TreatmentUpdate 122: October - Vol. 13, No. 6

English

Françaises

Expanded access to tenofovir
Programme d'accès élargi au ténofovir: HoseinSR; Tenofovir, also known as Viread, is a type of anti_HIV drug called a nucleotide reverse transcriptase inhibitor. Tenofovir is not a major breakthough — it is not as potent as, say, the protease inhibitor indinavir (Crixivan). However, advantages with tenofovir include once_daily dosing and it may be useful against HIV that is resistant to 3TC (Epivir, lamivudine). Tenofovir will likely be approved for use only in people who have previously used anti_HIV medications.
New formulation of ddI approved in Canada — Videx EC
Nouvelle formulation de ddI approuvée au Canada — Videx EC: HoseinSR; On October 4, 2001, Health Canada approved a new capsule formulation of the anti_HIV drug ddI (didanosine, Videx). The new formulation is called Videx EC and consists of a capsule filled with tiny beads of ddI. These beads are covered with a coating designed to protect them from the damaging effects of stomach acid.
AIDS and lymphoma
Le sida et le lymphome: HoseinSR; Like HIV, certain other viruses — such as HPV (human papilloma virus) and HHV-8 (human herpes virus-8) — are also sexually transmitted. Therefore, it should come as no surprise that some HIV positive people who also test positive for these other viruses can develop certain cancers caused by HPV (cervical and anal cancer) and HHV-8 (Kaposi's sarcoma).
Encouraging news on lymphoma from France
De nouvelles encourageantes au sujet du lymphome: HoseinSR; French researchers analysed data from medical records contained in a database on over 80,000 HIV positive subjects collected since 1989 from 69 hospitals. They also reviewed medical records on AIDS-related lymphoma from three major AIDS treatment centres in Paris — Hôpital Rothschild, CHU Pitié Salpêtrière and Hôpital de l'Institut Pasteur.
Chemo and HAART extend survival with lymphoma
La chimiothérapie et les médicaments anti-VIH prolongent la survie des patients atteints de lymphome: HoseinSR; Many studies suggest that the use of HAART can reduce the risk of developing AIDS-related infections. In those PHAs who develop the AIDS-related cancer called non-Hodgkin's lymphoma, the use of HAART combined with chemotherapy appears to prolong survival compared to the time when HAART was not available.
Can low-dose shark cartilage make Kaposi's sarcoma disappear?
Le cartilage de requin peut-il faire disparaître les lésions du SK?: HoseinSR; Kaposi's sarcoma (KS) is a tumour that usually appears on the skin and most commonly affects HIV positive men who have sex with other men. Not surprisingly, therefore, KS is caused by a sexually transmitted virus — HHV_8 (human herpes virus_8). Although there is no cure for KS, sometimes the use of highly active antiretroviral therapy (HAART), with or without chemotherapy, can help shrink and control KS lesions.
Cidofovir for KS lesions
Le cidofovir contre les lésions du SK?: HoseinSR; Treating the AIDS-related cancer Kaposi's sarcoma (KS) became easier with the introduction of HAART. Indeed, sometimes KS lesions would simply fade in HAART users without the need to resort to chemotherapy. As HIV develops resistance to HAART, the immune system again becomes weak, allowing previously controlled problems to flare up. Doctors in Verona and Rome, Italy, recently reported details about two HIV positive men who developed new KS lesions despite long-term use of HAART.
Looking at soluble CD23 levels to predict lymphoma
Le niveau de CD23 soluble comme prédicteur du lymphome: HoseinSR; As we noted in our first article on lymphoma, there isn't any quick and simple test to diagnose or predict which PHAs will develop this cancer. Nor are there any symptoms that specifically occur from having lymphoma. To try to remedy the situation, researchers in Italy have been monitoring levels of the a protein called soluble CD23 (sCD23) in the blood and fluid surrounding the brain — cerebrospinal fluid (CSF). They have found higher-than-normal levels of sCD23 in the CSF of PHAs who have brain lymphoma.

TreatmentUpdate 123: November/December - Vol. 13, No. 7: Can delavirdine substitute for ritonavir?; Hepatitis C treatment, HAART and side effects; Toxicity profile of HAART; Rosiglitazone for lipodstrophy?; Actos (pioglitazone); Focus on fat; Metformin — long-term results; Sugar blues and protease inhibitors; Glucose — from food to blood sugar; Lipodystrophy - introduction; Caution with nelfinavir and some lipid-lowering drugs; Trizivir approved in Canada;
TreatmentUpdate 122: October - Vol. 13, No. 6: Looking at soluble CD23 levels to predict lymphoma; Cidofovir for KS lesions; Can low-dose shark cartilage make Kaposi's sarcoma disappear?; Chemo and HAART extend survival with lymphoma; Encouraging news on lymphoma from France; AIDS and lymphoma; New formulation of ddI approved in Canada — Videx EC; Expanded access to tenofovir
TreatmentUpdate 121: September - Vol. 13, No. 5: SIDE EFFECTS - Andractim for HAART-associated breast enlargement; SIDE EFFECTS - Does efavirenz cause breast enlargement?; IMMUNE BOOSTERS - Interleukin-12 may be useful for hepatitis C; ANTI-HIV AGENTS - Study finds HIV subtly damages vision; ANTI-HIV AGENTS - Searching for the right dose of ritonavir-saquinavir; ANTI-HIV AGENTS - Different combinations of ritonavir-indinavir
TreatmentUpdate 120: August - Vol. 13, No. 4: Depression linked to immune system decline in women; Carnitine for high triglycerides; Lipid-lowering drugs and changes to diet can make a difference; Sexual dysfunction and HAART; Immune booster used to fight drug-resistant herpes; Effect of HAART on cervical growths; Switching to nevirapine — results after one year
TreatmentUpdate 119: July - Vol. 13, No. 3: Fosamax for HIV-related bone problems?; Indinavir and bones: Does thickness = strength?; Lipodystrophy — nukes vs. protease inhibitors; Spanish study looks at nevirapine's effect on the liver; Pesticides found in many ginseng supplements in the U.S.; Can ginseng help suppress HIV?; Large Italian study looks at when to start HAART;
TreatmentUpdate 118: June - Vol. 13, No. 2: Protease inhibitors and blood sugar problems; Indinavir - effect on sugar and insulin; Background on glucose — from food to blood sugar; Extra co-enzyme Q10 for statin-users?; Can vitamin E help people recover from hepatitis B?; Study examines link between low levels of zinc and survival; Zinc and the immune system;
TreatmentUpdate 117: May - Vol. 13, No. 1: Bone damage - more than just nukes involved; Australian study links nukes, lactic acid to bone loss;High levels of lactic acid in some users of HAART ;Nukes may be linked to hearing loss; Of power plants and energy shortages; German study finds whey protein supplement boosts antioxidants; Spanish doctors try switching therapy from month to month
TreatmentUpdate 115: February - Vol. 12, No. 11: St. John's wort found to lower nevirapine levels; Are deaths due to liver damage becoming more common?; St. John's wort extract found not helpful for hepatitis C; Canadian researchers study "immune healing"; Kaletra approved in Canada;
TreatmentUpdate 114: January - Vol. 12, No. 10: Some women may be at high risk for anal cancer; DHEA — Cautions and concerns; DHEA for depression?; Changes in DHEA levels in people taking anti-HIV therapy; DHEA — Background; Nukes linked to fat wasting; Triple nuke therapy — results after one year; Switching meds: from protease inhibitors to non-nukes
Copyright / Staff / How to Contact

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1990,2000. ÆGiS & the Sisters of Saint Elizabeth of Hungary. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS and the Sisters of Saint. Elizabeth of Hungary, or the party credited as the provider of the content. Please contact the party credited as the provider of the content for permission to reproduce.

TreatmentUpdate 122: October - Vol. 13, No. 6

Table Of Contents